Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRMS.L Regulatory News (RMS)

  • There is currently no data for RMS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Anglo-Indian Pro-Larva mask partnership

20 Aug 2021 07:00

RNS Number : 2421J
Remote Monitored Systems PLC
20 August 2021
 

Remote Monitored Systems plc

("RMS" or the "Company")

 

Anglo-Indian Pro-Larva mask partnership

 

 

The Board of RMS acknowledges the press release announced today by the British High Commission regarding its Anglo-Indian partnership to distribute its MHRA approved Pro-Larva mask in India:

 

 

The British High Commission is delighted to announce a new Anglo-Indian partnership between British technology firm Pharm 2 Farm Limited, a subsidiary of nanosynth group plc, and India's VKE Enterprises to distribute British MHRA approved Pro-Larva mask which is proven to kill Covid-19 and Influenza viruses, using unique patented nano-technology developed at Nottingham Trent University.

 

This important healthcare partnership introduces affordable technology that will help protect the Indian population, saving lives and supporting a developing healthcare market.

 

 

The Pro-Larva Face Mask is Made in Britain using ground-breaking patented α-Virion™ nanotechnology that is clinically approved to kill 99.9% of Covid and Influenza viruses, within 5 minutes of contact, and continues to kill the virus for seven hours.

 

The mask is the first ever anti-viral mask to be approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) as a Class 1 medical device.

 

British inventor Dr Gareth Cave, director of nanosynth group plc*, states: "The mask we've developed has been proven to inactivate viruses upon contact; the antiviral layer kills virus which has been blocked by the filter layers. The challenge with conventional surgical-type masks is that they only block virus from entering or exiting the mask. They don't have an active mechanism for killing it once it's trapped in the mask.

"Our new antiviral mask has been designed to utilise the existing barrier technology and combine it with our nanotechnology to kill the virus once it is trapped there.

 "We've added the barrier layer to both sides of the mask so not only does it protect the wearer but also those around. By killing the virus on contact, it also means that the used face mask can be safely disposed of and not be a potential source of passive transfer."

 

Vivek Kohli, Chair VKE Enterprises states: "I'm delighted to play a strategic role in the introduction of this cutting-edge British technology, that will keep my fellow country men and women safer. This is an exciting opportunity for a new Anglo-Indian partnership to do good in India.

 

"At this time, with so many countries continuing to struggle with Covid and an expected influenza surge later in the year, it's paramount for countries and their organisations to come together to support one another."

 

 

 

Graeme Todd- Business Development Manager at Pro-Larva said "With the initial negative impact Covid-19 had on India we were determined to make a difference with our technology. Talks have been ongoing for several months to find the correct partner who can deliver our unique product where needed. VKE Enterprises have stood out and we are proud to be working with them."

 

 

* Remote Monitored Systems name to be changed to nanosynth group plc on Monday 23rd August 2021

 

- ENDS -

 

ENQUIRIES:

Remote Monitored Systems plc

Antony Legge (Chairman) via IFC Advisory

 

SP Angel Corporate Finance LLP +44 20 3470 0470

Nominated Adviser and Joint Broker

Stuart Gledhill

Caroline Rowe

 

Peterhouse Capital Limited +44 20 7469 0930

Joint Broker

Lucy Williams

 

IFC Advisory Ltd +44 20 3934 6630

Graham Herring

Zach Cohen

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAXPNFSPFEFA
Date   Source Headline
24th Feb 202111:05 amRNSSecond Price Monitoring Extn
24th Feb 202111:00 amRNSPrice Monitoring Extension
18th Feb 20214:41 pmRNSSecond Price Monitoring Extn
18th Feb 20214:36 pmRNSPrice Monitoring Extension
18th Feb 20212:05 pmRNSSecond Price Monitoring Extn
18th Feb 20212:00 pmRNSPrice Monitoring Extension
18th Feb 20211:00 pmRNSUpdate on commissioning and board changes
12th Feb 20212:05 pmRNSSecond Price Monitoring Extn
12th Feb 20212:00 pmRNSPrice Monitoring Extension
12th Feb 20211:12 pmRNSResult of General Meeting
12th Feb 20217:00 amRNSGeneral Meeting – Link for webinar
9th Feb 20215:56 pmRNSShareholders’ Questions and Answers
8th Feb 20211:23 pmRNSExercise of Options
1st Feb 20211:08 pmRNSExercise of Options
1st Feb 20217:00 amRNSCommissioning delayed
29th Jan 20217:00 amRNSTotal Voting Rights
27th Jan 20217:00 amRNSNotice of General Meeting
26th Jan 20217:00 amRNSExercise of Options
25th Jan 20213:29 pmRNSExercise of Options
25th Jan 20217:00 amRNSExercise of Warrants
22nd Jan 20214:41 pmRNSSecond Price Monitoring Extn
22nd Jan 20214:36 pmRNSPrice Monitoring Extension
22nd Jan 20212:05 pmRNSSecond Price Monitoring Extn
22nd Jan 20212:00 pmRNSPrice Monitoring Extension
22nd Jan 202112:56 pmRNSEN14683 Certification, Commissioning Update
22nd Jan 20217:00 amRNSShare Option Grant update
21st Jan 20219:06 amRNSSecond Price Monitoring Extn
21st Jan 20219:00 amRNSPrice Monitoring Extension
18th Jan 20217:00 amRNSBoard appointment,update on mask production and GM
11th Jan 20216:26 pmRNSDirector Dealing
11th Jan 20217:00 amRNSBoard changes
8th Jan 20215:00 pmRNSDirector Option Exercise and Total Voting Rights
8th Jan 20217:00 amRNSDirector Option Exercise and Total Voting Rights
7th Jan 202110:52 amRNSStatement regarding share price movement
7th Jan 20219:05 amRNSSecond Price Monitoring Extn
7th Jan 20219:00 amRNSPrice Monitoring Extension
5th Jan 20217:00 amRNSPharm 2 Farm Update
4th Jan 20214:41 pmRNSSecond Price Monitoring Extn
4th Jan 20214:36 pmRNSPrice Monitoring Extension
4th Jan 20212:06 pmRNSSecond Price Monitoring Extn
4th Jan 20212:00 pmRNSPrice Monitoring Extension
4th Jan 202111:05 amRNSSecond Price Monitoring Extn
4th Jan 202111:00 amRNSPrice Monitoring Extension
31st Dec 202011:51 amRNSTotal Voting Rights
30th Dec 20207:00 amRNSPlanned Board Changes & Warrant Update
29th Dec 20207:00 amRNSPharm 2 Farm Update
23rd Dec 20208:13 amRNSUpdate on Fundraising & response to announcements
18th Dec 202011:05 amRNSSecond Price Monitoring Extn
18th Dec 202011:00 amRNSPrice Monitoring Extension
18th Dec 20209:51 amRNSPlacing to raise £5,000,000 and Issue of Warrants

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.